SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001798749-23-000056
Filing Date
2023-08-14
Accepted
2023-08-14 08:16:01
Documents
58
Period of Report
2023-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q tmb-20230630x10q.htm   iXBRL 10-Q 1947403
2 EX-10.1 tmb-20230630xex10d1.htm EX-10.1 36270
3 EX-31.1 tmb-20230630xex31d1.htm EX-31.1 9563
4 EX-31.2 tmb-20230630xex31d2.htm EX-31.2 9584
5 EX-32.1 tmb-20230630xex32d1.htm EX-32.1 5422
6 EX-32.2 tmb-20230630xex32d2.htm EX-32.2 5458
  Complete submission text file 0001798749-23-000056.txt   7469496

Data Files

Seq Description Document Type Size
7 EX-101.SCH tmb-20230630.xsd EX-101.SCH 32246
8 EX-101.CAL tmb-20230630_cal.xml EX-101.CAL 49573
9 EX-101.DEF tmb-20230630_def.xml EX-101.DEF 126429
10 EX-101.LAB tmb-20230630_lab.xml EX-101.LAB 315998
11 EX-101.PRE tmb-20230630_pre.xml EX-101.PRE 257632
52 EXTRACTED XBRL INSTANCE DOCUMENT tmb-20230630x10q_htm.xml XML 1576399
Mailing Address 930 WINTER STREET SUITE M-500 WALTHAM MA 02451
Business Address 930 WINTER STREET SUITE M-500 WALTHAM MA 02451 617-443-2400
Aerovate Therapeutics, Inc. (Filer) CIK: 0001798749 (see all company filings)

IRS No.: 831377888 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40544 | Film No.: 231166462
SIC: 2834 Pharmaceutical Preparations